Literature DB >> 31391797

Update on the Risk of Primary and Recurrent HCC With the Use of DAA Therapy for HCV Infection.

Jordan Feld1.   

Abstract

Entities:  

Year:  2019        PMID： 31391797      PMCID： PMC6676353     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  6 in total

1.  Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.

Authors:  Fabrice Carrat; Hélène Fontaine; Céline Dorival; Mélanie Simony; Alpha Diallo; Christophe Hezode; Victor De Ledinghen; Dominique Larrey; Georges Haour; Jean-Pierre Bronowicki; Fabien Zoulim; Tarik Asselah; Patrick Marcellin; Dominique Thabut; Vincent Leroy; Albert Tran; François Habersetzer; Didier Samuel; Dominique Guyader; Olivier Chazouilleres; Philippe Mathurin; Sophie Metivier; Laurent Alric; Ghassan Riachi; Jérôme Gournay; Armand Abergel; Paul Cales; Nathalie Ganne; Véronique Loustaud-Ratti; Louis D'Alteroche; Xavier Causse; Claire Geist; Anne Minello; Isabelle Rosa; Moana Gelu-Simeon; Isabelle Portal; François Raffi; Marc Bourliere; Stanislas Pol
Journal:  Lancet       Date:  2019-02-11       Impact factor: 79.321

Review 2.  Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.

Authors:  Reem Waziry; Behzad Hajarizadeh; Jason Grebely; Janaki Amin; Matthew Law; Mark Danta; Jacob George; Gregory J Dore
Journal:  J Hepatol       Date:  2017-08-09       Impact factor: 25.083

3.  Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.

Authors:  María Reig; Zoe Mariño; Christie Perelló; Mercedes Iñarrairaegui; Andrea Ribeiro; Sabela Lens; Alba Díaz; Ramón Vilana; Anna Darnell; María Varela; Bruno Sangro; José Luis Calleja; Xavier Forns; Jordi Bruix
Journal:  J Hepatol       Date:  2016-04-13       Impact factor: 25.083

Review 4.  AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.

Authors:  Amit G Singal; Joseph K Lim; Fasiha Kanwal
Journal:  Gastroenterology       Date:  2019-03-13       Impact factor: 22.682

5.  Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.

Authors: 
Journal:  J Hepatol       Date:  2016-06-07       Impact factor: 25.083

6.  Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.

Authors:  Amit G Singal; Nicole E Rich; Neil Mehta; Andrea Branch; Anjana Pillai; Maarouf Hoteit; Michael Volk; Mobolaji Odewole; Steven Scaglione; Jennifer Guy; Adnan Said; Jordan J Feld; Binu V John; Catherine Frenette; Parvez Mantry; Amol S Rangnekar; Omobonike Oloruntoba; Michael Leise; Janice H Jou; Kalyan Ram Bhamidimarri; Laura Kulik; Tram Tran; Hrishikesh Samant; Renumathy Dhanasekaran; Andres Duarte-Rojo; Reena Salgia; Sheila Eswaran; Prasun Jalal; Avegail Flores; Sanjaya K Satapathy; Robert Wong; Annsa Huang; Suresh Misra; Myron Schwartz; Robert Mitrani; Sasank Nakka; Wassim Noureddine; Chanda Ho; Venkata R Konjeti; Alexander Dao; Kevin Nelson; Kelly Delarosa; Usman Rahim; Meher Mavuram; Jesse J Xie; Caitlin C Murphy; Neehar D Parikh
Journal:  Gastroenterology       Date:  2019-01-18       Impact factor: 22.682
  6 in total
  2 in total

1.  Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma.

Authors:  Wei-Chen Lin; Yang-Sheng Lin; Chen-Wang Chang; Ching-Wei Chang; Tsang-En Wang; Horng-Yuan Wang; Ming-Jen Chen
Journal:  PLoS One       Date:  2020-05-22       Impact factor: 3.240

Review 2.  Roles of Thyroid Hormone-Associated microRNAs Affecting Oxidative Stress in Human Hepatocellular Carcinoma.

Authors:  Po-Shuan Huang; Chia-Siu Wang; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Int J Mol Sci       Date:  2019-10-21       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.